Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Neuroinflammatory Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD6 ECD-Fc / Domain-Specific Truncated Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CD6 Products |
| Gene Delivery | CD6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformationally intact for cell-based screening. |
View CD6 Products |
| Benchmark Ab | Anti-CD6 (Sequence of Itolizumab) Recombinant positive control antibody. Sequence verified. |
View CD6 Products |
| Validator | CD6 siRNA Set For knockdown verification in primary T cells or cell lines. |
View CD6 Products |
| Related Target A | ALCAM (CD166) Primary ligand of CD6. Crucial for CD6-ALCAM interaction blocking assays. |
View ALCAM Products |
| Related Target B | CD5 Scavenger receptor superfamily homolog. Essential for specificity and off-target screening. |
View CD5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-specific epitope mapping (D1 vs D3) | Truncated CD6 domain proteins (D1-D2 or D3-only) available with strict sequence verification. |
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Itolizumab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD6 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted T-cell modulation. CD6 is a key co-stimulatory receptor on T cells that interacts with ALCAM (CD166) on antigen-presenting cells or epithelial tissues. As first-generation therapies reach the clinic, the next wave of R&D is targeting domain-specific blocking (such as D1 vs D3 targeting) to achieve selective immunomodulation without inducing T-cell depletion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Non-depleting) | Equillium, Biocon | aGvHD, Lupus Nephritis, Psoriasis | ALCAM-CD6 blocking assay (Need high-purity CD6 and ALCAM ECD proteins) |
| Bispecific / Multi-specific | Academic institutions, Biotech startups | Autoimmune, Neuroinflammation | Heterodimer Validation (Need Cross-reactive Abs and ortholog proteins) |
| CAR-T (CD6-targeted) | Preclinical consortia | T-cell Lymphoma, T-ALL | Fratricide resistance verification (Need CD6 Lentivirus for stable knockout/knockin lines) |